The Cholesteryl Ester Transfer Protein pipeline drugs market research report outlays comprehensive information on the Cholesteryl Ester Transfer Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cholesteryl Ester Transfer Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Metabolic Disorders, Cardiovascular, Central Nervous System, and Infectious Disease which include the indications Dyslipidemia, Heterozygous familial hypercholesterolemia (heFH), Cardiovascular, Cardiovascular Disease, Alzheimer’s Disease, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Cholesteryl Ester Transfer Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Cholesteryl Ester Transfer Protein pipeline targets constitutes close to seven molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 2, 1, 1, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Cholesteryl Ester Transfer Protein overview
Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.
For a complete picture of Cholesteryl Ester Transfer Protein’s drug pipeline, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
